Related Experiment Video
Updated: Aug 17, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
Safely slowing down the decline in Alzheimer's disease: gene therapy shows potential
1Discovery Bioscience, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK. martin.braddock@astrazeneca.com
Abstract:
The role of nerve growth factor in stimulating cholinergic function, loss of which is a cardinal feature in Alzheimer's disease, has been documented for many years from preclinical animal model studies. This anabolic growth factor has been delivered into the forebrain of patients with mild Alzheimer's disease using transfer of autologous fibroblasts engineered to produce nerve growth factor. A Phase I clinical study shows that fibroblast transfer and growth factor expression is well tolerated and the rate of cognitive decline in patients is improved, correlating with an increase in metabolic activity detected in the cortex.
Related Concept Videos
Alzheimer's Disease: Treatment
Gene Therapy
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
